The Creating and Restoring Equal Access to Equivalent Samples Act clears US Senate Judiciary Committee.  During markup, Sens. Hatch, R-Utah, and Cornyn, R-Tex., preview future amendments that would benefit innovators.

Democrats on US Senate Health Committee express concern that patient cost sharing could increase significantly with the change.

HHS Secretary Azar explains why companies have not voluntarily lowered prices as yet, despite President Trump’s recent comments. He also discussed using regulations to prohibit rebates.

HHS endorsement of company-sponsored discount programs for cash-paying customers with Medicare would be preferable to lowering list pricing.

Part D plans project rebates will increase to 25.3% of total drug costs in their bids for the 2018 benefit year, the recently-released Medicare Trustees Report notes.